(Q50553046)

English

Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.

scientific article published on 17 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

D A Kelly

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

B Haber

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

R P González-Peralta

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

K F Murray

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

M M Jonas

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

J P Molleston

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

M R Narkewicz

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

F R Sinatra

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

T Lang

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

A Lachaux

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

S Wirth

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

M Shelton

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

H S Te

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

H Pollack

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

W Deng

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

S Noviello

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

J K Albrecht

17

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

publication date

17 November 2011

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

263-270

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

Guidance for clinical trials for children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Chronic hepatitis C in children: the pathological and clinical spectrum.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Clinical longitudinal standards for height and height velocity for North American children

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Treatment of hepatitis C in liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long term follow-up of patients with chronic hepatitis C treated with interferon alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Impact of chronic hepatitis B and interferon-alpha therapy on growth of children

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Hepatitis C in children: a quaternary referral center perspective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01544.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2011.01544.X

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22404724

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50553046&oldid=1540640562"